Tracy MacNeal is a chemical engineer turned healthcare executive who serves as President and CEO of Materna Medical, a women's health technology company in Mountain View, California. With more than 25 years across pharmaceuticals, diagnostics, digital health and medical devices, and six transactions to her name, she has built a career on commercializing hard-to-define products and opening markets that others overlook. She sits on the board of AdvaMed and chairs its Women's Executive Network, and she is known for pairing engineering rigor with a storyteller's instinct for building trust with clinicians, investors and customers.

Daniel (Dan) Wagner is a medical device and biotechnology executive who leads Otolith Labs, the Washington, DC company building the OtoBand, a non-invasive wearable that uses patented non-invasive Vestibular Resonance Therapy (nVRT) to address chronic vertigo. With more than two decades of commercial experience spanning 60-plus countries and roles at Spark Biomedical, Olympus Corporation, HeartSciences and Signature Biologics, Wagner advised Otolith for over five years before joining full-time as Chief Commercial Officer in 2024 and now serves as Chief Executive Officer, steering the company's go-to-market strategy toward a planned market launch.
Eric Gornstein is the Chief Executive Officer of Pearl Diagnostics, a Johns Hopkins spinout in Baltimore that makes MycoMEIA, the first FDA-cleared urine test for invasive aspergillosis. A biopharma commercialization veteran with more than 25 years leading product launches, partnering and deal-making across therapeutic areas, he joined Pearl in late 2025 to take the company from FDA clearance to the market and into Europe. Earlier he helped launch Radius Health's first product, Tymlos, and worked in business development and cell therapy partnerships at companies including bit.bio and Talaris Therapeutics.
James Reinstein is the President and CEO of Conformal Medical, a New Hampshire medical device company building next-generation left atrial appendage occlusion (LAAO) technology to reduce stroke risk in patients with atrial fibrillation. A three-decade medtech operator, he spent 17 years at Boston Scientific in commercial leadership across Asia, Europe and Latin America before running a string of device companies as CEO, including Cutera, Drawbridge Health, Aptus Endosystems and Saranas. Known for insisting that a device company think commercially from day one, he took the helm at Conformal in 2022 to guide its foam-based CLAAS system through pivotal trials toward market.
Fogarty Innovation is a nonprofit medtech incubator and education organization on the El Camino Health campus in Mountain View, California. Founded in 2007 by legendary surgeon-inventor Thomas J. Fogarty, MD, it helps early-stage medical device companies cross the gap from novel idea to clinical reality through hands-on coaching, education programs, and a network of 300+ industry experts. In October 2025 it merged with New York's Cardiovascular Research Foundation to become CRF's West Coast innovation hub.
Andrea Ashford-Hicks is the CEO of Cayuga Biotech, an early-stage platform biotechnology company developing biomimetic polyphosphate therapies for severe bleeding. She joined in 2022 after two decades in biopharma, including leading the FDA approval and commercial launch of RETHYMIC at Enzyvant Therapeutics and progressive roles at Johnson & Johnson, Pfizer, Agenus, EMD Serono and Schering-Plough. She holds dual degrees in biology and finance from the University of Pennsylvania and the Wharton School.
Darrin Miles is the President and CEO of Nested Therapeutics, a Cambridge, Massachusetts precision oncology company that launched in 2022 with $125 million in financing to hunt for cancer-driving mutations hiding in plain sight. A commercialization leader with more than two decades in healthcare, Miles spent 14 years at Genentech shepherding landmark cancer brands and later served as Chief Commercial Officer at Agios Pharmaceuticals, where he helped bring the first mutant-IDH therapies to acute myeloid leukemia patients. At Nested, he is translating computational biophysics, genomics, and chemical biology into drugs aimed at targets the rest of the field calls undruggable.
David Stoffel is the Chief Business Officer of RapidAI, the clinical-AI company whose stroke-imaging algorithms helped rewrite the rules of how strokes get treated. A medical doctor who chose boardrooms over bedsides, he has spent more than two decades turning ambitious medical technologies into standards of care - from the da Vinci surgical robot at Intuitive Surgical to mobile cardiac telemetry at iRhythm and point-of-care EEG at Ceribell. At RapidAI he runs the commercial engine: marketing, clinical affairs, education, customer success, corporate development, and finance.